Literature DB >> 26248811

Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study.

Neda Amiri1, Mary De Vera2, Hyon K Choi3, Eric C Sayre4, J Antonio Avina-Zubieta5.   

Abstract

OBJECTIVE: To determine the risk of newly recorded myocardial infarction (MI) and stroke among incident GCA cases compared with controls from the general population. We also evaluated time trends during follow-up.
METHODS: We conducted a matched cohort study (1996-2010) of all patients with incident GCA from the province of British Columbia, Canada. We estimated incidence rates of MI and stroke according to GCA disease duration. We calculated hazard ratios (HRs), adjusting for potential confounders.
RESULTS: Among 809 individuals with GCA (mean age 75.9 years, 75.8% female), 83 developed MI and 60 developed stroke, with corresponding incidence rates of 38.1 and 26.4/1000 person-years, respectively. Compared with non-GCA cases, the age-, sex- and entry time-matched HRs were 2.75 (95% CI 2.16, 3.50) for MI and 2.21 (95% CI 1.68, 2.91) for stroke. When other covariates were adjusted for, the corresponding HRs were 1.77 (95% CI 1.29, 2.43) and 2.04 (95% CI 1.43, 2.93). The age-, sex- and entry time-matched HRs for MI and stroke were highest during the first year after GCA diagnosis [4.76 (95% CI 3.29, 6.88) and 3.20 (95% CI 2.11, 4.87), respectively].
CONCLUSION: These findings provide general population-based evidence that GCA patients are at a substantially increased risk of cardiovascular disease. Increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted for GCA patients.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cardiovascular disease; giant cell arteritis; myocardial infarction; stroke; vasculitis

Mesh:

Year:  2015        PMID: 26248811     DOI: 10.1093/rheumatology/kev262

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  11 in total

1.  Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia.

Authors:  Shubhasree Banerjee; Mohammadhadi Bagheri; Veit Sandfort; Mark A Ahlman; Ashkan A Malayeri; David A Bluemke; Jianhua Yao; Peter C Grayson
Journal:  Semin Arthritis Rheum       Date:  2018-09-17       Impact factor: 5.532

Review 2.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

Review 3.  An Updated Review of Cardiovascular Events in Giant Cell Arteritis.

Authors:  Hubert de Boysson; Achille Aouba
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

Review 4.  Giant Cell Arteritis: 2018 Review.

Authors:  Anne Winkler; David True
Journal:  Mo Med       Date:  2018 Sep-Oct

5.  All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Authors:  Bahar Moghaddam; Shelby Marozoff; Lingyi Li; Eric C Sayre; J Antonio Aviña- Zubieta
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

6.  Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study.

Authors:  Alberto Lo Gullo; Matthew J Koster; Cynthia S Crowson; Ashima Makol; Steven R Ytterberg; Antonino Saitta; Carlo Salvarani; Eric L Matteson; Kenneth J Warrington
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

7.  Atypical presentation of giant cell arteritis in a patient with vertebrobasilar stroke: A case report.

Authors:  Ahmed Mohamed Elhfnawy; Michael Bieber; Mira Schliesser; Peter Kraft
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

8.  Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis.

Authors:  Donatienne de Mornac; Christian Agard; Jean-Benoit Hardouin; Mohamed Hamidou; Jérôme Connault; Agathe Masseau; Alexandra Espitia-Thibault; Mathieu Artifoni; Chan Ngohou; François Perrin; Julie Graveleau; Cécile Durant; Pierre Pottier; Antoine Néel; Olivier Espitia
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-27       Impact factor: 5.346

9.  Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.

Authors:  Sara Gale; Huong Trinh; Katie Tuckwell; Neil Collinson; John H Stone; Khaled Sarsour; Jinglan Pei; Jennie Best; Christine Birchwood; Shalini V Mohan
Journal:  Rheumatol Ther       Date:  2019-02-01

10.  A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis.

Authors:  Wolfgang A Schmidt; Bhaskar Dasgupta; Raashid Luqmani; Sebastian H Unizony; Daniel Blockmans; Zhihong Lai; Regina H Kurrasch; Ivana Lazic; Kurt Brown; Ravi Rao
Journal:  Rheumatol Ther       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.